Back to search results

Reduced Dose Radiotherapy for Indolent Non-Hodgkin Lymphoma

This study is looking at whether a reduced dose of radiation therapy is as safe and effective as the standard dose for people with indolent non-Hodgkin lymphoma (a slow-growing type of blood cancer). Standard radiation treatment usually involves 12 sessions. This trial will compare that to a reduced dose, which could be 3, 2, or 5 sessions. The main goal is to see if the reduced dose causes fewer side effects (adverse events) within 14 days after treatment. Researchers will also look at how well the treatment works, quality of life, and how long people stay cancer-free. You may be able to join if you are 18 or older and have certain types of indolent B-cell lymphoma, whether it's newly diagnosed, has come back, or hasn't responded to previous treatments.

Study design
This is a Phase II interventional study with a planned enrollment of 112 participants. It compares different reduced radiation doses to the standard radiation dose.
What's involved
You would undergo CT (computed tomography) or PET/CT scans, possibly an endoscopy, and receive either 3, 5, or 12 sessions of involved-site radiation therapy.
Compensation
Not stated in the trial record.
Follow-up
The study will assess acute side effects up to 14 days after radiation treatment, and will also evaluate late toxicity.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06386315

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
Mayo Clinic
~112 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:Computed TomographyEndoscopic ProcedureInvolved-site Radiation Therapy (3 Fractions)Involved-site Radiation Therapy (12 Fractions)Positron Emission TomographyQuestionnaire Administration

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of grade 2 or higher acute adverse events (AEs)
Measured over Up to 14 days after radiation treatment

Conditions

Indolent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent B-Cell Non-Hodgkin Lymphoma
Refractory Indolent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent Non-Hodgkin Lymphoma
Refractory Indolent Non-Hodgkin Lymphoma

Explore related trials

Indolent B-Cell Non-Hodgkin Lymphoma

NCT06386315

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic Health System - Mankato

    Mankato, Minnesotastudy coordinator listed

    Recruiting

  • Mayo Clinic Health System in Albert Lea

    Albert Lea, Minnesotastudy coordinator listed

    Recruiting

  • Mayo Clinic Health System-Eau Claire Clinic

    Eau Claire, Wisconsinstudy coordinator listed

    Recruiting

  • Mayo Clinic Health System-Franciscan Healthcare

    La Crosse, Wisconsinstudy coordinator listed

    Recruiting

  • Mayo Clinic in Arizona

    Scottsdale, Arizonastudy coordinator listed

    Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Floridastudy coordinator listed

    Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Brad S. Hoppe, MD, MPH · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Histological confirmation of indolent B-cell lymphoma that can include any of the following:
Follicular lymphoma (grade 1 or 2 or 3A)
Marginal zone lymphoma (nodal or extranodal)
Follicle center lymphoma
Any stage disease
Initial, refractory, or relapsed disease. If relapse involves the site to be treated there must be evidence of disease progression
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 3
Negative pregnancy test done ≤ 7 days prior to registration, for persons of childbearing potential only
Provide written informed consent
Ability to complete questionnaire(s) by themselves or with assistance
Willing to return to enrolling institution for follow-up visits (during the active monitoring phase of the study). Virtual visits can also be considered as an option for applicable items
Confirmation from radiation oncologist of suitability to participate in study

Exclusion

Any of the following:
Pregnant women
Nursing women
Women of childbearing potential who are unwilling to employ adequate contraception
T-cell lymphoma
Receiving treatment for small and chronic lymphocytic lymphoma
Grade 3B follicular lymphoma

What this trial measures

  • Incidence of grade 2 or higher acute adverse events (AEs)Up to 14 days after radiation treatment

    AEs will be graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Acute toxicity will be reported as a proportion calculated as the number of patients with acute toxicity divided by the total number of treatment patients. Treatment cycles are 5 days ±2 days (Arm 1) and 16 days ±2 days (Arm 2).